RTW Investments LP raised its holdings in Exagen Inc. (NASDAQ:XGN – Free Report) by 2.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,391,184 shares of the company’s stock after buying an additional 26,848 shares during the period. RTW Investments LP owned about 0.08% of Exagen worth $3,381,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Stonepine Capital Management LLC raised its stake in Exagen by 21.4% in the first quarter. Stonepine Capital Management LLC now owns 1,037,074 shares of the company’s stock valued at $2,520,000 after buying an additional 183,032 shares during the period. Perkins Capital Management Inc. raised its stake in Exagen by 3.0% in the first quarter. Perkins Capital Management Inc. now owns 259,905 shares of the company’s stock valued at $632,000 after buying an additional 7,500 shares during the period. UBS Group AG raised its stake in Exagen by 3.9% in the third quarter. UBS Group AG now owns 136,813 shares of the company’s stock valued at $370,000 after buying an additional 5,144 shares during the period. State Street Corp raised its stake in Exagen by 3.6% in the first quarter. State Street Corp now owns 132,023 shares of the company’s stock valued at $1,060,000 after buying an additional 4,579 shares during the period. Finally, Brinker Capital Investments LLC raised its stake in Exagen by 30.6% in the first quarter. Brinker Capital Investments LLC now owns 93,218 shares of the company’s stock valued at $749,000 after buying an additional 21,825 shares during the period. Institutional investors own 40.85% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $6.00 price objective on shares of Exagen in a research note on Tuesday, August 22nd.
Exagen Stock Performance
Shares of NASDAQ XGN traded down $0.01 during trading hours on Friday, reaching $2.39. 6,587 shares of the stock were exchanged, compared to its average volume of 8,708. The firm has a market capitalization of $40.30 million, a price-to-earnings ratio of -1.18 and a beta of 1.17. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.96 and a current ratio of 5.96. Exagen Inc. has a 52 week low of $2.04 and a 52 week high of $4.75. The stock’s fifty day simple moving average is $2.59 and its 200 day simple moving average is $2.68.
Exagen (NASDAQ:XGN – Get Free Report) last announced its earnings results on Monday, August 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The company had revenue of $14.14 million for the quarter, compared to analyst estimates of $10.97 million. Exagen had a negative return on equity of 74.00% and a negative net margin of 66.41%. Sell-side analysts predict that Exagen Inc. will post -1.62 EPS for the current year.
Exagen Company Profile
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- Five stocks we like better than Exagen
- The How and Why of Investing in Gold Stocks
- MarketBeat Week in Review – 9/4 – 9/8
- How Can Investors Use the Dogs of the Dow Strategy?
- The Best 5 Small Cap AI Companies to Buy Now
- How to Invest in the Best Canadian Stocks
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.